Azithromycin Treatment vs Placebo in Children With Respiratory Syncytial Virus-Induced Respiratory Failure: A Phase 2 Randomized Clinical Trial.

JAMA Netw Open · 2020 · PMC7180420 · PMID 32324238

Europe PMC DOI

hedged sentence

0.4900

closest p · 9.8× alpha

0.4900

boldest claim

The sentences

did not reach statistical significanceP = .49not close (p > 0.1)

On day 3 of treatment, the mean (SD) RSV load was lowest in the high-dose AZM group, at 0.1 (0.1) log 10 PFU/mL compared with 1.1 (0.4) log10 PFU/mL in the standard-dose AZM group, and 0.4 (0.3) log 10 PFU/mL in the placebo group, but this did not reach statistical significance ( P = .49) (eFigure 3A and 3B in Supplement 2 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.